Many companies lose money during their startup and product development years.
Here are a few of them:
On Feb. 21, 2014 the Houston, TX-based drilling and marine services company’s (NASDAQ: HERO) volume was robust, with 4,059,807 shares changing hands, significantly higher than its three-month average volume of 3,532,429 shares.
Full Year 2013 Results Disappointing
For the twelve month period ended Dec. 31, 2013, Hercules reported a loss from continuing operations of $26.8 million, or $0.17 per diluted share, on revenue of $858.3 million, compared to a loss from continuing operations of $121.0 million, or $0.79 per diluted share, on revenue of $618.2 million for the twelve month period ended December 31, 2012.
While it can be said that Hercules Offshore is losing a lot less money these day, the fact is it is still bleeding red.
On Feb. 21, the share price of HERO closed at $4.54, down 3 cents from previous day‘s share price of $4.57.
Find out what could be the best investor’s move when it comes to HERO by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Another company that has reported losing money when it reports is Endocan Corp. (NASDAQ OTC: ENDO). On Feb. 21 the company had volume of 3,183,771 shares in line with its three-month average of 3,236,038 shares.
The Dallas-TX-based company develops over-the-counter medications for aliments. But so far, these products are still in developmental stages.
Medical Marijuana Business
On Nov. 21, 2013 Endocan announced that it had signed a licensing agreement with Cannabis Science, Inc., (NASDAQ OTC: CBIS) a U.S. company specializing in cannabis formulation-based drug development. Under the agreement, Endocan was granted rights to use patent N2010968, entitled "Composition for the Treatment of Neurobehavioral Disorders", for Endocan studies, research and development, and consumer products.
Slow to Release Financials
Since then, there has been no news of the company’s progress in developing products. Endocan has been slow to release financial filings. In fact, its last financials date back two years ago to the year ending Dec. 31. 2013, at which time, Endocan reported a net income of -$3.3million.
On Feb. 21, the share price of ENDO closed at 11 cents, down 1 cent from previous day‘s share price of 10 cents.
Find out what could be the best investor’s move when it comes to ENDO by getting the complete report here, or by cutting and pasting the following link in your Web browser:
New Source of Funding
Peregrine Pharmaceutical Inc. (NASDAQ: PPHM) shares soared Feb. 21, with 3,416,578 shares changing hands, significantly higher than it three-month average of 2,967,926 shares.
On Feb 11, the Tustin, Calif.-based biopharmaceutical company announced that it had priced an underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock at a public offering price of $25.00 per share. Holders of Series E Preferred Stock may convert their shares, in whole or in part, into shares of the Company’s common stock at a conversion price of $3.00 per share. Gross proceeds to the Company are expected to be approximately $17.5 million before deducting the underwriting discount and other estimated offering expenses. The offering was expected to close on or about February 19, 2014.
It’s good that Peregrine has found some new funding.
Latest Financials 2012
That’s because Peregine’s last financials released Apr. 30, 2012 do not paint a pretty financial picture, with the company reporting a net income of about -$30 million. On Feb. 21, the share price of PPHM closed at 1.83 cents, up 7 cents from previous day‘s share price of $1.76.
Find out what could be the best investor’s move when it comes to PPHM by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Rights to Two New Anti-Cancer Agents
Cell Therapeutics Inc. (NASDAQ:CTIC) share price is still riding the recent positive announcement from its President and CEO James A. Bianco M.D. regarding the addition of two anti-cancer agents from Novartis to its portfolio.
“Regaining full rights to these two anti-cancer agents -- one currently marketed in Europe and the other completing late-stage development -- provides us with the flexibility to manage these assets within the context of our overall product portfolio strategy,” Bianco, said in a written statement.
New Director Appointed
In the beginning of the month, Cell Therapeutics announced that Karen Ignagni has been appointed a director. Ms. Ignagni currently serves as president CEO of America's Health Insurance Plans, which is the trade association representing U.S. health plans, serving members that provide healthcare, long-term care, dental and disability benefits to more than 200 million Americans.
On Feb. 21, the share price of CTIC closed at $3.42, up 16 cents unchanged from the previous day on volume of 3,036,999.
Find out what could be the best investor’s move when it comes to CTIC by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.sixfigurestockpicks.com/
Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.